-
Nutlin-3a: MDM2 Inhibitor Mechanism & Uses
2026-09-01
Nutlin-3a is a small-molecule MDM2 inhibitor that occupies the TP53-binding pocket and supports p53 pathway activation. It is a research tool for studying cell cycle arrest, apoptosis induction, and genotype-dependent responses in cancer models.
-
MLN4924 Workflow for Neddylation Research
2026-08-31
MLN4924 provides a selective way to interrogate NAE-dependent protein degradation, from rapid cullin target engagement to cell-cycle and tumor-model phenotypes. Its use as a pathway perturbation tool also enables mechanistic testing of the DCAF7–CRL4B antiviral axis, while highlighting why context and assay timing matter.
-
Bovine Insulin for Stress-Aware Cell Culture
2026-08-31
Bovine insulin is more than a routine media supplement: it is a controllable metabolic variable in reproducible cell culture. This guide connects insulin from bovine pancreas with ER-stress-aware assay design, using recent HBV–HMGB1 research to sharpen interpretation without overstating translational evidence.
-
Metformin Hydrochloride in AMPK Fibrosis Research
2026-08-30
Metformin Hydrochloride is a practical tool for connecting metabolic regulation with tissue remodeling. This workflow translates rabbit vocal fold fibrosis findings into assay-ready choices for AMPK, TGF-β, collagen, and glucose-metabolism studies while highlighting controls and reproducibility limits.
-
QPRT, P2Y11, and Breast Cancer Invasion
2026-08-29
The reference study identifies quinolinate phosphoribosyltransferase (QPRT) as a driver of breast cancer cell migration and invasion, linking altered NAD+ metabolism to myosin light chain phosphorylation and purinergic signaling. Its genetic and pharmacological experiments position P2Y11-linked signaling as a mechanistic research target, while also showing why the findings require validation across tumor models and clinical cohorts.
-
miR-18a–ALOXE3 Axis in Glioblastoma
2026-08-28
Yang et al. identify a miR-18a–ALOXE3 regulatory axis that links lipid metabolism to ferroptosis resistance and glioblastoma-cell migration. Their human-tumor analyses, cellular perturbations, lipid mediator studies, and orthotopic models support ALOXE3 as a mechanistic tumor suppressor rather than merely a disease-associated marker.
-
RNAi Screen Reveals SARS-CoV-2 Release Factors
2026-08-28
Kerr et al. developed an arrayed, druggable-genome RNA interference screen that measured SARS-CoV-2 production at multiple stages of the replication and reinfection cycle. The study identifies Rab11a-linked vesicular transport as a conserved proviral pathway and shows that CDK9 inhibition can block viral release, while also clarifying the experimental limits of host-targeted antiviral interpretation.
-
I-BET151 Workflows for Cancer Research
2026-08-27
I-BET151 (GSK1210151A) offers a practical way to probe BRD2, BRD3, and BRD4-dependent transcription in cancer models. This guide connects BET inhibition with apoptosis, cell cycle, chromatin, and prostate cancer disulfidptosis workflows while emphasizing controls, solvent handling, and interpretation limits.
-
SNS-032: CDK Biology from Cancer to Virology
2026-08-27
SNS-032 (BMS-387032) links selective CDK2, CDK7, and CDK9 inhibition with measurable changes in cell-cycle and transcriptional signaling. This article develops an assay-centered framework that distinguishes direct kinase effects from downstream transcriptional collapse and evaluates what SARS-CoV-2 host-factor research can—and cannot—add to cancer studies.
-
Gastric Cancer Assembloids Add Patient-Matched Stroma
2026-08-26
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal subpopulations, including fibroblast, endothelial, and mesenchymal cell populations. The model altered gene-expression profiles and drug responses relative to organoid monocultures, providing a more physiologically relevant platform for studying tumor–stroma interactions and treatment resistance.
-
Cistanche Nanovesicles Relieve Sertoli Cell Arrest
2026-08-26
A version 1 reference study reports that Cistanche deserticola exosome-like nanovesicles protect against cyclophosphamide-associated testicular injury by delivering miR159b-3p to Sertoli cells and suppressing the cell-cycle inhibitor P21. The work connects nanovesicle uptake through heparan sulfate proteoglycans with restoration of CDK1 activity, providing a mechanistic basis for further preclinical investigation of male reproductive toxicity.
-
DiscoveryProbe FDA-approved Drug Library for AML
2026-08-25
Use a clinically familiar compound collection to move from AML viability hits to mechanism-resolved PANoptosis assays. The DiscoveryProbe FDA-approved Drug Library supports efficient drug repositioning screening, orthogonal validation, and target-focused follow-up with ready-to-use DMSO stocks.
-
Lanabecestat (AZD3293) in BACE1 Workflows
2026-08-25
Lanabecestat (AZD3293) enables controlled BACE1 enzyme inhibition for linking amyloid-beta production inhibition with neuronal function assays. This practical guide outlines dose-ranging, medium-based amyloid measurements, optical electrophysiology, and troubleshooting strategies for Alzheimer’s disease research.
-
KPT-330 (Selinexor) Experimental Workflows
2026-08-24
KPT-330 (Selinexor) connects CRM1-dependent nuclear export biology with practical oncology and osteoclast assays. This workflow-focused guide covers stock preparation, dose selection, target-engagement readouts, xenograft translation, and troubleshooting for reproducible cancer research.
-
EPZ5676: A Selective DOT1L Inhibitor Workflow
2026-08-24
EPZ5676 combines subnanomolar biochemical potency with exceptional DOT1L selectivity, making it useful for connecting H3K79 methylation inhibition to leukemia-cell phenotypes. This workflow also shows how to extend target-engagement assays toward innate immune signaling and combination studies in multiple myeloma.